['hypercholesterolemia']
['placebo (for alirocumab)', 'alirocumab', 'lipid-modifying therapy (lmt)']

        Inclusion criteria:

        Participants with heterozygous familial hypercholesterolemia or non-familial
        hypercholesterolemia who were not adequately controlled with a stable daily dose of statin
        with or without other lipid modifying therapy, at stable dose prior to the screening visit
        (Week -3).

        Exclusion criteria:

          1. LDL-C <100 mg/dL (<2.59 mmol/L) at the screening visit in participants with
             heterozygous familial hypercholesterolemia or in participants with non-familial
             hypercholesterolemia who had a history of documented coronary heart disease as
             described in Japan Atherosclerosis Society (JAS) Guidelines for Prevention of
             Atherosclerotic Cardiovascular Diseases 2012.

          2. LDL-C <120 mg/dL (<3.10 mmol/L) at the screening visit in participants with
             non-familial hypercholesterolemia who had a history of documented diseases or other
             risk factors as categorized in primary prevention category III as described in JAS
             Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012.

          3. Not on a stable daily dose of lipid modifying therapy (including statin) within 4
             weeks prior to the screening visit or between screening and randomization visits.

          4. Age <20 years at the screening visit.

        The above information is not intended to contain all considerations relevant to a
        participants' potential participation in a clinical trial.
      